Table 2.
RBD-binding and pseudovirus neutralizing antibody titers of participants after propensity score matching.
| Time point | Low-dose group |
High-dose group |
||||||
|---|---|---|---|---|---|---|---|---|
| n | One-dose trial | Two-dose trial | p value | n | One-dose trial | Two-dose trial | p value | |
| RBD-binding antibody | ||||||||
| Day 0 | 34 | 21.5 (18.6, 24.9) |
20.7 (19.3, 22.3) |
.654 | 29 | 21.4 (18.7, 24.5) |
20.0 (20.0, 20.0) |
.326 |
| 28 days after the last dose | 34 | 456.9 (285.7, 730.7) |
604.7 (411.0, 890.0) |
.352 | 29 | 491.3 (320.2, 753.8) |
422.3 (289.4, 616.1) |
.589 |
| 6 months after the last dose | 34 | 59.5 (41.4, 85.5) |
285.3 (179.1, 454.3) |
<.001 | 29 | 57.7 (39.4, 84.6) |
178.0 (126.7, 250.1) |
<.001 |
| Pseudovirus neutralizing antibody | ||||||||
| Day 0 | 34 | 6.0 (4.9, 7.3) |
5.6 (5.0, 6.3) |
.538 | 29 | 5.5 (4.9, 6.2) |
5.4 (4.9, 6.0) |
.750 |
| 28 days after the last dose | 34 | 55.2 (34.8, 87.4) |
96.4 (70.3, 132.0) |
.026 | 29 | 46.3 (28.6, 75.1) |
104.9 (77.0, 143.0) |
.005 |
| 6 months after the last dose | 34 | 25.1 (17.6, 35.9) |
32.2 (20.7, 50.1) |
.376 | 29 | 25.7 (17.1, 38.7) |
41.6 (29.6, 58.4) |
.069 |
Antibody titers were compared at timepoints of before and after the last vaccination. Data are GMT (95% CI) and p value. n = the number of participants after propensity score matching. Bold indicates p < 0.05.